Vigadrone

Active Ingredient(s): Vigabatrin
FDA Approved: * June 21, 2018
Pharm Company: * AUCTA PHARMS
Category: Anticonvulsant

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Vigadrone Overview

Vigabatrin, brand name Sabril, is a medication used to treat epilepsy. It became available as a generic medication in 2019.[1] It works by inhibiting the breakdown of γ-aminobutyric acid (GABA). It is also known as γ-vinyl-GABA, and is a structural analogue of GABA, but does not bind to GABA receptors.[2] Contents 1 Medical uses 1.1 Epilepsy 1.2 Others 2 Adverse effects 2.1 Central nervous system 2.2 Gastrointestinal 2.3 Body as a whole 2.4 Tera...

Read more Vigadrone Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Vigabatrin

Recent Vigadrone Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Vigabatrin
  • For Solution: 500mg/packet
  • Tablet: 500mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Vigadrone: (1 result)

Sorted by National Drug Code
  • 0245-0556 Vigadrone 50 mg/ml Oral Powder, for Solution by Upsher-smith Laboratories, LLC

Other drugs which contain Vigabatrin or a similar ingredient: (2 results)